Treatment of medullary thyroid carcinoma: an update.
Prognosis and treatment effectiveness of medullary thyroid carcinoma (MTC) are largely related to the tumour stage, so that early diagnosis represents an important goal for the management of patients. Recent advances in genetic testing have improved the clinical approach to the familial MTC syndromes. There is general agreement that the primary operation for MTC should obtain the complete removal of the neoplastic tissue in the neck, because any adjuvant treatment has never been proven to be effective. The management of residual/recurrent or metastatic MTC still remains controversial, although a multimodal approach to advanced disease may be of value in palliation or local control of tumour progression. The role of surgery, external radiotherapy, radionuclide therapy and medical treatment, including biological response modifiers and cytotoxic drugs, are reviewed and discussed.
Orlandi
F
F
Department of Internal Medicine, S. Luigi Hospital, University of Turin, Italy. fabio.orlandi@unito.it
Caraci
P
P
Mussa
A
A
Saggiorato
E
E
Pancani
G
G
Angeli
A
A
D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000097:blood; D018276:Carcinoma, Medullary / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009367:Neoplasm Staging; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
D002116:Calcitonin